cDC1 dysregulation in cancer: An opportunity for intervention

Conventional dendritic cells driven by the transcription factor Batf3 (cDC1 cells) are critical for the activation and maintenance of tumor-specific CD8(+) T cells. In this issue of JEM, Lin et al. (https://doi.org/10.1084/jem.20190673) demonstrate systemic dysfunction of cDC1 cells in pancreatic ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Gajewski, Thomas F., Cron, Kyle R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2020
Materias:
Insights
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398176/
https://www.ncbi.nlm.nih.gov/pubmed/32697286
http://dx.doi.org/10.1084/jem.20200816
_version_ 1783565909674164224
author Gajewski, Thomas F.
Cron, Kyle R.
author_facet Gajewski, Thomas F.
Cron, Kyle R.
author_sort Gajewski, Thomas F.
collection PubMed
description Conventional dendritic cells driven by the transcription factor Batf3 (cDC1 cells) are critical for the activation and maintenance of tumor-specific CD8(+) T cells. In this issue of JEM, Lin et al. (https://doi.org/10.1084/jem.20190673) demonstrate systemic dysfunction of cDC1 cells in pancreatic cancer, which offers potential treatment strategies to expand the benefit of checkpoint blockade immunotherapy.
format Online
Article
Text
id pubmed-7398176
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-73981762021-02-03 cDC1 dysregulation in cancer: An opportunity for intervention Gajewski, Thomas F. Cron, Kyle R. J Exp Med Insights Conventional dendritic cells driven by the transcription factor Batf3 (cDC1 cells) are critical for the activation and maintenance of tumor-specific CD8(+) T cells. In this issue of JEM, Lin et al. (https://doi.org/10.1084/jem.20190673) demonstrate systemic dysfunction of cDC1 cells in pancreatic cancer, which offers potential treatment strategies to expand the benefit of checkpoint blockade immunotherapy. Rockefeller University Press 2020-07-22 /pmc/articles/PMC7398176/ /pubmed/32697286 http://dx.doi.org/10.1084/jem.20200816 Text en © 2020 Gajewski and Cron http://www.rupress.org/terms/https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Insights
Gajewski, Thomas F.
Cron, Kyle R.
cDC1 dysregulation in cancer: An opportunity for intervention
title cDC1 dysregulation in cancer: An opportunity for intervention
title_full cDC1 dysregulation in cancer: An opportunity for intervention
title_fullStr cDC1 dysregulation in cancer: An opportunity for intervention
title_full_unstemmed cDC1 dysregulation in cancer: An opportunity for intervention
title_short cDC1 dysregulation in cancer: An opportunity for intervention
title_sort cdc1 dysregulation in cancer: an opportunity for intervention
topic Insights
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398176/
https://www.ncbi.nlm.nih.gov/pubmed/32697286
http://dx.doi.org/10.1084/jem.20200816
work_keys_str_mv AT gajewskithomasf cdc1dysregulationincanceranopportunityforintervention
AT cronkyler cdc1dysregulationincanceranopportunityforintervention

Ejemplares similares